Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study

Background: The fixed combination of extrafine beclometasone dipropionate 100 μg/formoterol 6 μg (extrafine BDP/F) delivered by NEXThaler has proved to be effective in patients with moderate-to-severe asthma in terms of lung function, symptoms and asthma control. The aim of this study was to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakakos, Petros, Chatziapostolou, Panagiotis, Katerelos, Panos, Efstathopoulos, Petros, Korkontzelou, Aliki, Katsaounou, Paraskevi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876660/
https://www.ncbi.nlm.nih.gov/pubmed/35207635
http://dx.doi.org/10.3390/jpm12020146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876660/
https://www.ncbi.nlm.nih.gov/pubmed/35207635
http://dx.doi.org/10.3390/jpm12020146

Ejemplares similares